Ypsomed's YpsoMate 5.5 mL autoinjector has been recognized with the Drug-Device Combination Innovation Award at the CPHI Celebration Awards 2026 in China. Presented as part of the InnoPack Awards category, it recognizes forward-looking companies and groundbreaking products that drive innovation across the pharmaceutical and medical packaging industries.
The award highlights the innovation behind YpsoMate 5.5 mL and its contribution to advancing drug-device combination products. Designed for 5.5 mL prefilled syringes and compatible with multiple primary containers suppliers with both 8 mm and half inch needle configurations, the platform expands the possibilities for self-administration of large-volume therapies through a novel, ergonomic design, clear user feedback during injection, and adaptability to a broad range of drug and delivery requirements. These capabilities support the evolving needs of pharmaceutical companies developing next-generation high-dose biologics and other complex treatments.
This recognition reflects the dedication, expertise, and collaboration of the teams involved in bringing YpsoMate 5.5 mL to market. Winning the award at CPHI China marks an important milestone for the platform and reinforces Ypsomed's commitment to advancing self-injection technology.
YpsoMate 5.5 mL is Ypsomed's large-volume autoinjector platform for 5.5 mL prefilled syringes. Taking handheld self-injection beyond volumes of 2.0 mL, it combines the market-proven two-step handling principle of the YpsoMate family with flexible performance across a broad range of fill volumes, viscosities and injection times, supporting high-dose delivery.
